Pharmaids Pharmaceuticals Limited share price
BSE: PHARMAID
Key numbers
- Market cap
- ₹ 107 Cr
- Current price
- ₹ 30.40
- 52-week high / low
- ₹ 66 / 26
- Stock P/E
- -
- Book value
- ₹ 13.4
- Dividend yield
- 0.00%
- ROCE
- -15.4%
- ROE
- -21.9%
- Debt to equity
- 0.49
- Sales growth (3 yrs)
- -
- Profit growth (3 yrs)
- -
- 1-year return
- -46.5%
About Pharmaids Pharmaceuticals Limited
Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides contract research and manufacturing services for pharma, biotech, agro, and chemical industries in India. It provides pharma intermediates, such as Dichloro Benzoyl nitrile, hydrazine carboximidamide 2 methane, pyridine carbonitrile, pyridine carboxylic acid, 8-chloro-10, 11-dihydro-4-aza-5H-dibenzo cycloheptene-5-one, 8-chloro-6,11-dihydro-11 cyclohepta pyridine, 2-amino-5-methylthiopene-3-carbonitrile, 5-methyl-2-amino thiophene-3-carbonitrile, 4-amino-2-methyl-10h-thiene benzodiazepine hydrochloride, 2,4-diamino-6-chloropyrimidine, hydronopol, squalene, 5-chloro-3-phenylanthranil, 2-amino-2,5-dichlorobenzophenone, 6-fluoro-3-4-piperidinyl-1,2-benzisoxazole hcl, 3-2-methyl-4H-pyrido pyrimidin-4-one, 4-n-hexyl resorcinol, triazole kopoxil, CAB-60, CABER-4, CAB-70, DTV, avobenzone, nopol, hydronopol, and narwedine. The company also offers active pharmaceuticals ingredients, including voglibose, silodosin, vitamin K2-7, UDCA, P5P, fluralaner, afoxolaner, maropitant, grapiprant, firocoxib, carprofen, loratadine, desloratadine, lamotrigine, gliclazide, and minoxidil. Pharmaids Pharmaceuticals Limited was…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 7 | 9 | 5 | 7 | 4 |
| Operating profit | -5 | -5 | -3 | -0 | -1 |
| Net profit | -5 | -2 | -2 | -2 | 2 |
| EPS (₹) | -1.41 | -0.70 | -0.70 | -0.51 | 0.63 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.